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Objectives. We sought to examine coronary arteries for the
presence of viable bacteria of the fastidious species Chlamydia
pneumoniae.
Background. The respiratory pathogen C. pneumoniae has been
implicated in the pathogenesis of coronary artery disease (CAD).
Previous studies have demonstrated an antichlamydial serore-
sponse to be a cardiovascular risk factor and coronary athero-
mata to contain chlamydial components in varying proportions.
Endovascular demonstration of replicating bacteria is required to
provide evidence for an infectious component in CAD and a
rationale to discuss antimicrobial therapy.
Methods. Myocardial revascularization was performed in 70
patients. Atherosclerotic lesions from 53 coronary endarterectomy
and 17 restenotic bypass samples were cultured and subjected to
nested polymerase chain reaction (PCR) for C. pneumoniae.
Antichlamydial immunoglobulin G (IgG), IgA and IgM was
examined by microimmunofluorescence.
Results. Viable C. pneumoniae was recovered from 11 (16%) of
70 atheromata, and chlamydial deoxyribonucleic acid (DNA) was
detected in 21 (30%) of 70 atheromata; 17 nonatherosclerotic
control samples were PCR-negative (p < 0.01). Fifteen (28%) of 53
endarterectomy and 6 (35%) of 17 bypass samples were PCR-
positive. DNA sequencing of six different PCR products did not
reveal differences between coronary isolates and respiratory ref-
erence strains, suggesting that common respiratory strains gain
access to the systemic circulation. Serologic results did not
correlate with direct detection results and did not identify indi-
vidual endovascular infection.
Conclusions. A significant proportion of atherosclerotic coro-
nary arteries harbor viable C. pneumoniae. This finding supports
the hypothesis of a chlamydial contribution to atherogenesis.
Whether chlamydiae initiate atherosclerotic injury, facilitate its
progression or colonize atheromata is unknown. However, the
endovascular presence of viable bacteria justifies a controlled
clinical investigation of antimicrobial treatment benefit in the
therapy and prevention of CAD.
(J Am Coll Cardiol 1998;31:827–32)
©1998 by the American College of Cardiology
Chlamydia pneumoniae has been established as an important
respiratory pathogen (1–3). The obligate intracellular bacte-
rium is characterized by its extraordinarily high prevalence:
seroepidemiologic results indicate that virtually everyone be-
comes infected at least once during their lifetime (2). As
chlamydiae are notorious for causing persistent disease with
severe tissue destruction, concern about sequelae from recur-
rent chlamydial infection is justified. In this respect, Saikku et
al. (4) related chronic coronary artery disease (CAD) with
previous or persistent C. pneumoniae infection. Based on
antichlamydial immunoglobulin G (IgG) elevation and the
presence of immune complexes with chlamydial lipopolysac-
charides in patients with CAD, C. pneumoniae infection was
suggested as an independent cardiovascular risk factor (4,5).
After initial concerns, these surprising results were reproduced
wherever the attempt was made in a microimmunofluores-
cence test system (6–8), as well as by immunoblot procedures
(9). However, the indirect statistical associations could not be
taken as evidence of causality.
Endovascular infection might provide an explanation for
unclear phenomena of atherogenesis, like mesenchymal cell
proliferation and the distinct inflammatory component (10). A
contribution of C. pneumoniae in this respect requires its
presence in diseased arteries, and several investigators have
reported an occurrence of pathogen-specific nonviable struc-
tures in atheromatous plaques, although detection rates varied
widely with the techniques employed (11–13). Because chla-
mydiae are susceptible to antimicrobial therapy, their role in
the development of coronary arteriosclerosis might result in a
radical change in current clinical practice. However, an anti-
bacterial treatment approach will only succeed in the presence
of viable pathogens in a substantial proportion of atheroma-
tous lesions, and mere demonstration of bacterial fragments
cannot justify chemotherapy. We therefore sought to study
viable bacteria in the atherosclerotic arteries to provide an
indication and ethical basis for an investigational antibacterial
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treatment for CAD. The limitation of this approach lies in the
difficulty in isolating C. pneumoniae by cell culture procedures.
In spite of the unusually frequent occurrence of the pathogen
in the respiratory tract, there are ,50 continuously viable
strains available worldwide. However, recent improvements in
chlamydial cell culture render this approach more promising
now (14). Culture results were supplemented by a nested
polymerase chain reaction (PCR) method for C. pneumoniae
genomic DNA to detect potentially viable chlamydiae nonrep-
licative in culture.
Methods
Coronary surgery was performed in 70 patients (60 men, 10
women; mean age 63 years, range 34 to 82) requiring elective
or urgent myocardial revascularization because of total or
subtotal coronary occlusion with a preserved coronary periph-
ery. Established cardiovascular risk factors were frequent:
diabetes mellitus (36%), plasma cholesterol .5 mmol/liter
(57%), systolic blood pressure .140 mm Hg (70%) and
tobacco smoking (24%). None of the patients reported a
recent respiratory infection. Coronary samples for direct de-
tection of C. pneumoniae were collected from 53 of the patients
during coronary endarterectomy: after a longitudinal incision,
atherosclerotic cylinders were obtained by blunt dissection of
the occluding plaque from the adventitial layer. Atheromatous
samples from 17 patients were obtained from restenotic bypass
lesions. Immediately after harvesting, plaques were collected
in a defined C. pneumoniae transport medium for protection of
chlamydial viability (15). Perioperatively obtained sera were
tested for anti–C. pneumoniae IgG, IgA and IgM activity in a
microimmunofluorescence assay (Labsystems, Helsinki, Fin-
land), according to the manufacturer’s instructions.
Atherosclerotic tissues were cut into 0.3-cm segments and
separately ground in a tissue homogenizator in culture medium
at 4°C. Three segments per coronary sample were used. Each
plaque suspension was divided for PCR and cell culture. The
culture protocol was adapted from a recently described proce-
dure (14). Briefly, plaque suspensions were centrifuged (1,000 g,
35°C, 45 min) onto HEp-2 host cell monolayers in multiwell
tissue culture plates. Supernatants were removed, and the
cultures were incubated for 3 days at 35°C, 5% carbon dioxide,
in serum-free isolation medium (Eagle’s minimal essential
medium, nonessential amino acids, 2 mmol/liter glutamine; all
from Gibco/BRL, Eggenstein, Germany), supplemented with
1 mg/ml cycloheximide (Sigma) in at least 10 serial passages.
Chlamydial growth was identified by immunofluorescence
microscopy: inclusions containing replicating C. pneumoniae
were stained with fluorescein isothiocyanate– conjugated
C. pneumoniae–specific mouse monoclonal antibody, accord-
ing to the manufacturer’s instructions (Cellabs, Sydney, Aus-
tralia). Viable strains were continually propagated.
C. pneumoniae DNA was detected by a nested PCR method
recently evaluated for carotid atherectomy tissues (16). Before
amplification, DNA was purified by proteinase K digestion and
cetyltrimethylammonium bromide treatment (17). Amplifica-
tion relied on the species-specific HL-1/HR-1 primer pair,
which amplifies a 438-base pair (bp) C. pneumoniae target
sequence of unknown function (18), and on the nested IN-1/2
primer pair, which yields a 128-bp product (16). For confirma-
tion and enhancement of sensitivity, nonradioactive DNA
hybridization was performed using, as the probe, oligonucleo-
tide HM-1 (18), 39-labeled with digoxigenin-ddUTP (Boehr-
inger GmbH, Mannheim, Germany). Strategies to prevent
false positive results from contamination vigorously adhered to
recent guidelines (19). For control purposes, seven coronary
arteries as well as 10 segments from the aortic wall, without
macroscopic evidence of atherosclerosis (13 men and 4 wom-
en; mean age 49 years, range 24 to 73), were available for PCR
testing and were examined as described earlier. These samples
were obtained at autopsy or from explanted hearts. The rates
of chlamydial presence in atherosclerotic and healthy samples
were compared using the chi-square test. The presence of
chlamydiae in the coronary endarterectomy samples and in the
restenotic bypass samples was compared in the same manner.
Strains isolated from vascular tissue might differ from the
common respiratory isolates. For this reason and for confir-
mation of the identification, cardiovascular isolates were com-
pared with the respiratory reference strains CWL-029 (Amer-
ican Type Culture Collection VR 1310) and MUL-1 (14) by
DNA amplification involving four diagnostic PCR primer pairs
known to specifically identify C. pneumoniae (Table 1) (20–
23). Published sequence variations within the chlamydial lipo-
polysaccharide biosynthesis gene waaA (kdtA) were used to
derive genus-specific (184/1049) (24) and species-specific (781/
1279) primers. Sequences of the 781/1279 primers are 59TG-
GCTTCCTGTAGTGCAGAA39 and 59ATGCTCTCCATG-
TACGGTCA39, respectively. Mobility of amplification
products was determined by agarose-gel electrophoresis. For
Abbreviations and Acronyms
CAD 5 coronary artery disease
DNA 5 deoxyribonucleic acid
Ig 5 immunoglobulin
PCR 5 polymerase chain reaction
Table 1. Origin of Primer Pairs Used for PCR Analysis of Viable
Cardiovascular C. pneumoniae Isolates
Gene
PCR Primer
Pair
Amplicon
Size (bp) Study (ref no.)
53-kd protein 53z1/2 499 Kubota (20)
76-kd protein 17/1697 1681 Perez et al. (21)
16S rRNA CpnA/B 465 Gaydos et al. (22)
dnaK 431/934 504 Kornak et al. (23)
waaA (kdtA) 184/1049* 866 Essig et al. (24)
waaA (kdtA) 781/1279 499 Present study
*Specific at genus level, all other primers specific at species level. bp 5 base
pair; PCR 5 polymerase chain reaction; ref 5 reference.
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further examination of possible differences between cardiovas-
cular and respiratory strains, all PCR products from CWL-029
and the cardiovascular isolates CV-1 and CV-2 were purified
and cloned into vector pCR2.1 (Invitrogen, Leek, The Neth-
erlands). DNA sequences were then determined on both
strands of the clones by standard DNA sequencing methodol-
ogy.
Results
Replicating C. pneumoniae isolates were recovered by cell
culture from the occluded coronary arteries of 11 (16%) of 70
patients, indicating that viable chlamydia commonly thrive in
atherosclerotic human arteries. Six isolates could be perma-
nently propagated by serial subcultures. Isolates were identi-
fied by immunofluorescence in the second to fifth passages.
Isolation of the strains was successful in all three arterial
segments examined for six patients and in two segments for
three patients. In two patients, one segment only yielded a
viable isolate. Strains were consecutively designated CV-1 to
CV-11. An immunofluorescence stain of CV-1 is shown in
Figure 1.
The nested PCR protocol yielded positive results in the
arterial samples of 21 (30%) of 70 patients (Table 2). All
culture-positive patients were PCR-positive. Nine of the pa-
tients with a parallel positive culture result had positive PCR
results in all three separately examined coronary artery seg-
ments; two were positive in two segments. Of the 10 patients
without culturally retrievable chlamydiae, seven were positive
for chlamydial DNA in three segments, and three were positive
Figure 1. Immunofluorescence stain reveals infection of HEp-2 host
cells with replicating C. pneumoniae isolated from the occluded
coronary artery of a 62-year old man (passage 15 after primary
isolation). Multiple inclusions in the host cells are characteristic of C.
pneumoniae. This cardiovascular strain is morphologically identical to
the common respiratory isolates.
Table 2. Clinical and Serologic Characteristics of 21 Patients With a Positive Result by Polymerase
Chain Reaction for C. pneumoniae Genomic Deoxyribonucleic Acid in Their Occluded Coronary
Arteries Do Not Aid in Identifying Individual Endovascular Infection
Pt No./
Gender Age (yr)
Coronary
Sample
Established Cardiovascular
Risk Factors
Viable C. pneumoniae
Strain Isolated
MIF-IgG
Titer
MIF-IgA
Titer
1/M 62 CEA SBP, CHOL, TSM CV-1 64 32
2/F 62 BYP SBP, CHOL 64 , 16
3/F 66 CEA CHOL, TSM CV-2 16 , 16
4/M 55 CEA TSM 128 64
5/M 52 CEA SBP, CHOL, DM,
TSM
32 , 16
6/M 68 CEA SBP, CHOL CV-3 64 32
7/F 57 BYP SBP, CHOL 256 , 16
8/M 68 CEA CHOL, DM CV-4 16 , 16
9/M 67 CEA SBP, CHOL, DM CV-5 2,048* 256*
10/M 68 BYP SBP, CHOL, DM CV-6 512* , 16
11/M 72 CEA SBP 512* 64
12/M 67 CEA — 256 16
13/M 71 CEA CHOL 64 32
14/M 60 CEA SBP 64 , 16
15/M 79 CEA SBP, DM 16 , 16
16/M 69 BYP SBP, CHOL, DM 32 , 16
17/M 54 CEA SBP, CHOL, TSM CV-7† 64 , 16
18/M 65 CEA SBP, CHOL, DM CV-8† 32 , 16
19/F 60 CEA — CV-9† 512* , 16
20/M 63 BYP SBP, DM CV-10† 256 , 16
21/F 49 BYP SBP, CHOL CV-11† 512* , 16
*Significantly elevated titer consistent with acute infection according to common criteria. †Strain lost viability in the
cell culture system during subcultures. SBP 5 systolic blood pressure . 140 mm Hg; BYP 5 atheromatous lesion from
restenotic coronary bypass; CEA 5 coronary endarterectomy sample; CHOL 5 plasma cholesterol . 5 mmol/liter;
DM 5 diabetes mellitus; F 5 female; IgA 5 immunoglobulin A; IgG 5 immunoglobulin G; M 5 male; MIF 5
microimmunofluorescence assay; Pt 5 patient; TSM 5 tobacco smoking.
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in two segments. Positive results from any given single segment
were reproducible. No positive results were obtained from the
17 control samples without macroscopically evident atheroscle-
rosis. This difference in chlamydial DNA detection results
between atherosclerotic samples and healthy control material
was significant by the chi-square test (p # 0.01). Endarterec-
tomy samples as well as restenotic bypass lesions harbored C.
pneumoniae: 15 (28%) of 53 endarterectomy and 6 (35%) of 17
restenotic bypass samples were PCR-positive (Table 2). This
difference in chlamydial DNA detection between endarterec-
tomy and restenotic bypass samples was not significant by the
chi-square test.
Serology was not useful in identifying patients with proven
endovascular C. pneumoniae infection. Only six of the 21
infected patients had significantly elevated IgG titers ($512)
consistent with recent infection, according to generally ac-
cepted microimmunofluorescence test interpretation criteria
(Table 2) (2). In contrast, such elevated IgG titers were also
found in six patients without detectable chlamydiae. Sixty-two
(89%) of 70 patients were seropositive for chlamydial IgG,
including all those with a positive direct detection result.
Immunoglobulin A seropositivity, which is considered related
to short- or long-term chlamydial infection, was 46%: 7 (33%)
of 21 of the infected patients and 25 (51%) of 49 of those
without verified infection were IgA-positive. Firm criteria for
interpretation of antichlamydial IgA are lacking, but distinctly
elevated IgA titers ($256) occurred in one patient with
endovascular infection and in two without infection. Specific
anti–C. pneumoniae IgM was not detected. Clinical character-
istics did not aid in differentiation of the patient groups, either.
The established cardiovascular risk factors were similarly dis-
tributed in patients with and without verified coronary artery
infection. Interestingly, patients with a positive direct detection
result did not report a recent respiratory infection, nor did
their initial clinical investigation reveal signs of infection.
Table 2 shows microimmunofluorescence titers and clinical
characteristics of patients with a positive direct detection
result.
DNA amplification and sequence analysis permitted un-
equivocal identification of C. pneumoniae strains isolated from
atheromatous plaques and suggested high conservation among
the genes for the 53- and 76-kd proteins, as well as for dnaK,
waaA (kdtA) and 16S rRNA. As shown in Figure 2, the
continuously viable vascular strains invariably yielded amplifi-
cation products of the predicted size in each experiment,
identical to those obtained for the respiratory reference
strains. Sequence analysis of PCR products derived from the
reference strain CWL-029 and cardiovascular strains CV-1 and
CV-2 revealed 100% sequence identity (data not shown).
Therefore, vascular and respiratory strains could not be distin-
guished.
Discussion
Presence of viable chlamydiae in atheromata. Coronary
artery disease has an infectious component: a significant
proportion of coronary arteries occluded by atheromata har-
bor viable bacteria. We have culturally isolated replicating C.
pneumoniae from 11 (16%) of 70 atherosclerotic samples
obtained during myocardial revascularization. The PCR results
indicate that true chlamydial infection in CAD may even be
more frequent: genomic C. pneumoniae DNA was detected in
30% of atherectomy tissues. This finding can also be consid-
ered as evidence for the presence of viable pathogens; extrinsic
DNA is usually rapidly degraded by restriction endonucleases.
There was no evidence of C. pneumoniae in 17 nonatheroscle-
rotic control samples. These results imply a chlamydial role in
the pathogenesis of CAD, but even the endovascular presence
of multiplying bacteria is not final proof of their etiologic role
in coronary arteriosclerosis. In contrast, purely commensal
existence of replicative bacteria in inflamed but otherwise
sterile tissue is not very plausible.
Respiratory epithelium is the primary target of C. pneu-
moniae. How the chlamydiae gain access to the arteries is
unclear, but infected monocytes/macrophages are potential
vectors for dissemination (13). A preliminary analysis yielded
Figure 2. Polymerase chain reaction products
generated with C. pneumoniae reference strains
CWL-029 (lane 1) and MUL-1 (lane 2) and six
cardiovascular isolates (lanes 3 to 8). Primer pairs
53z 1/2 for the 53-kd protein gene were applied to
panel A, 781/1279 and 184/1049 for waaA to
panels B and C, respectively, 431/934 for dnaK
to panel D, 17/1697 for the 76-kd protein gene to
panel E and CpnA/CpnB for 16S rRNA to panel
F. Lane 9 contains the negative control; the
marker lanes (M) contain the 1-kb ladder (Gibco/
BRL). Amplification products of pulmonary and
cardiovascular isolates do not differ in electro-
phoretic mobility, indicating that the common
respiratory strains gain access to the systemic
circulation and the sites of coronary arterioscle-
rosis. Further genetic analysis is needed to detect
possible specific characteristics of vascular strains
that may be linked to vascular pathology.
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no obvious differences between reference strains from the
respiratory tract and the newly recovered cardiovascular iso-
lates with regard to size and sequence of six different PCR
products. Thus, it is possible that the common respiratory
strains, known to infect virtually everyone repeatedly during
their lifetime, gain access to the systemic circulation. However,
a more detailed analysis of the now-available cardiovascular
isolates will reveal whether they have strain-specific character-
istics in their genetic background that may be linked to
cardiovascular pathology.
Previous studies. Attempts to directly detect endovascular
chlamydiae have produced rather conflicting results, with
positivity rates varying between 2% and 100%; healthy arteries
did not contain chlamydiae (11–13,25,26). Immunostaining
usually produced the highest positivity rates. Thus, immuno-
fluorescence staining revealed 79% of coronary atheromata to
contain structures conforming with chlamydial inclusions (25).
However, a potentially decreased specificity of those immuno-
logic detection techniques, when applied to atheromatous
lesions, has been considered a problem (27). This is avoided by
use of DNA amplification or cultural isolation, but only
isolation can unequivocally demonstrate chlamydial viability—
the prerequisite for successful antimicrobial treatment. The
recent improvements of culture conditions (14) made the
recovery of viable chlamydiae from a substantial proportion of
plaques in the present study now possible. Notorious difficul-
ties to recover C. pneumoniae have contributed to its late
discovery in 1986 (1). Previous attempts of chlamydial cell
culture isolation from the coronary arteries have been futile,
with the exception of a single strain recently reported
(12,26,28). It is not surprising that DNA amplification yielded
a higher positivity rate than did culturing in our study. A
clinically relevant two- to threefold enhanced sensitivity of
PCR is known from respiratory samples (3). In spite of the use
of optimized cell culture protocols, the attempt to recover
primary isolates is commonly unsuccessful. Whether this is due
to the artificial environment provided by the isolation system
or the bacteria remaining in a viable but nonreplicative state of
persistence is not known. The distribution of chlamydiae in the
coronary arteries is apparently uneven, as we were not able to
detect chlamydiae in every single fragment from an infected
plaque. Therefore, the rate of vessels actually infected may
even be higher than that found in our study. As other arterial
tissues can be affected, too, the vascular presence of chlamyd-
iae appears to be a generalized phenomenon of atherosclerotic
diseases not limited to the coronary arteries (16,29).
Antimicrobial therapy and CAD. The endovascular pres-
ence of viable bacteria provides an indication and the ethical
base required for investigational studies of antimicrobial ther-
apy in CAD. Interestingly, chlamydiae are recovered from
primary atheromatous lesions as well as from secondary re-
stenotic bypass lesions at a similar rate (28% vs. 35%). Thus, C.
pneumoniae may also be involved in the inflammatory pro-
cesses leading to bypass restenosis. Patients undergoing coro-
nary artery bypass graft surgery might comprise a group in
which a potential benefit of antimicrobial therapy might be-
come evident within a limited period. Macrolide antibiotics are
probably suitable, as respiratory C. pneumoniae strains are
susceptible to them (30), but dosages and duration of therapy
have not yet been defined. Recovery of the vascular isolates
now permits us to conduct antimicrobial susceptibility tests
with the potentially atherogenetically relevant strains. Some
preliminary data indicating potential benefit of antimicrobial
therapy in severe CAD are available (31,32), but much more
extensive investigations are required before any conclusion
regarding possible advantages of antichlamydial treatment in
CAD can be made. Currently we do not even know whether
chlamydiae exist in a continuously replicative state susceptible
to antimicrobial therapy in the atherosclerotic plaques, or
whether they can enter a persistent state of limited replication
resulting in a very limited susceptibility to antibacterial agents.
Because neither microimmunofluorescence serology nor clini-
cal characteristics could identify individual patients with endo-
vascular infection, we are lacking a valid variable to predict the
risk of coronary artery infection. Diagnostic procedures that
depend on coronary atherectomy samples are obviously too
late in the course of the disease, and the development of
criteria to specify the individual risk of endovascular chlamyd-
ial infection remains a diagnostic challenge.
Conclusions. Atherosclerosis shares many attributes with
chronic inflammatory disease. Raised expression of adhesion
molecules and cytokines, influx and proliferation of smooth
muscle cells and fibroblasts and transendothelial migration and
accumulation of macrophages play key roles in atherogenesis
(10,33). These pathologic alterations within the vascular wall
are believed to be initiated by an as yet undefined vascular
injury. Initiation of the atherosclerotic lesion as well as pro-
motion of preexisting vascular damage by chlamydial infection
is certainly conceivable, but the final experimental evidence for
an etiologic role in vascular pathology definitely requires the
establishment of C. pneumoniae infection (and its subsequent
eradication) in an animal model—a difficult effort, as the
pathogenicity appears naturally limited to humans, although
some progress has been reported (34). Success of antibacterial
treatment studies might provide empiric evidence for an
etiologic role of C. pneumoniae in the progression of coronary
arteriosclerosis. However, fulfillment of Koch’s postulates or
their molecular correlates (35) for C. pneumoniae and coro-
nary arteriosclerosis cannot be expected over a short course of
time. The contribution of chlamydiae to the development of
atherosclerosis is a fascinating hypothesis that may initiate a
radical change in clinical practice for one of the leading causes
of death—CAD.
We acknowledge the skillful technical assistance of Angela Gravenhorst, Uta
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